Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.353 CHF
174.92 M CHF
1.54 B CHF
278.25 M
About Exelixis, Inc.
Sector
CEO
Michael M. Morrissey
Headquarters
Alameda
Website
Founded
1994
FIGI
BBG00LVDBHF4
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where EX9 is featured.
Frequently Asked Questions
The current price of EX9 is 29.686 CHF — it has increased by 49.60% in the past 24 hours. Watch EXELIXIS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange EXELIXIS INC stocks are traded under the ticker EX9.
EX9 stock has risen by 49.60% compared to the previous week, the month change is a 49.60% rise, over the last year EXELIXIS INC has showed a 49.60% increase.
We've gathered analysts' opinions on EXELIXIS INC future price: according to them, EX9 price has a max estimate of 32.94 CHF and a min estimate of 19.94 CHF. Watch EX9 chart and read a more detailed EXELIXIS INC stock forecast: see what analysts think of EXELIXIS INC and suggest that you do with its stocks.
EX9 stock is 33.16% volatile and has beta coefficient of −0.04. Track EXELIXIS INC stock price on the chart and check out the list of the most volatile stocks — is EXELIXIS INC there?
Today EXELIXIS INC has the market capitalization of 8.46 B, it has increased by 15.42% over the last week.
Yes, you can track EXELIXIS INC financials in yearly and quarterly reports right on TradingView.
EXELIXIS INC is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
EX9 earnings for the last quarter are 0.34 CHF per share, whereas the estimation was 0.29 CHF resulting in a 17.88% surprise. The estimated earnings for the next quarter are 0.33 CHF per share. See more details about EXELIXIS INC earnings.
EXELIXIS INC revenue for the last quarter amounts to 457.22 M CHF, despite the estimated figure of 415.50 M CHF. In the next quarter, revenue is expected to reach 479.70 M CHF.
EX9 net income for the last quarter is 99.97 M CHF, while the quarter before that showed 203.29 M CHF of net income which accounts for −50.82% change. Track more EXELIXIS INC financial stats to get the full picture.
No, EX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 6, 2024, the company has 1.31 K employees. See our rating of the largest employees — is EXELIXIS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EXELIXIS INC EBITDA is 538.93 M CHF, and current EBITDA margin is 10.74%. See more stats in EXELIXIS INC financial statements.
Like other stocks, EX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EXELIXIS INC stock right from TradingView charts — choose your broker and connect to your account.